Since 2005, Dr. Tonelli has been the co-leader of a joint initiative between the University of Alberta and the Hospital Civil de Guadalajara, aimed at prevention of kidney failure among the poor of Jalisco, Mexico. Consultant: Merck (honorarium donated to charity) Speaker: Merck (honorarium donated to charity) Christoph Wanner, MD (Work Group Co-Chair), is Head of Nephrology, Department of Medicine at University of Wu rzburg, where he also obtained his MD. He then trained in Internal Medi- cine and subsequently Nephrology, in Freiburg, Germany. Dr Wanner has maintained an active research interest in the role of lipids in progression of kidney disease, having participated in two major trials conducted in this area: 4D and SHARP. His research also includes the elucidation of the inflammatory response syndrome in diabetic nephropathy, CKD and ESRD; pathogenesis and treatment for Fabry disease; and identification of risk factors for CKD progression and CVD in large study cohorts. Dr. Wanner has authored over 400 publications, including serving presently as Editor-in-Chief of Journal of Renal Nutrition and editorial board member for Clinical Nephrology, Current Opinion in Nephrology & Hyper- tension, Kidney International, and Nephrology Dialysis Trans- plantation. He is also President of the International Society of Renal Nutrition and Metabolism and Chairman of ERA-EDTA Renal Registry. In recognition of his contributions to nephrology, he was awarded the International Distinguished Medal from the US NKF in 2007 and nominated as honorary member of the Polish Society of Nephrology in 2011. In 2012 he obtained a doctor honoris causa from the Charles University of Prague. 